These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2503257)

  • 1. Ifosfamide in pediatric malignant solid tumors.
    Pratt CB; Douglass EC; Etcubanas EL; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S24-7. PubMed ID: 2503257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of ifosfamide in children with malignant solid tumors.
    Pratt CB; Horowitz ME; Meyer WH; Etcubanas E; Thompson EI; Douglass EC; Wilimas JA; Hayes FA; Green AA
    Cancer Treat Rep; 1987 Feb; 71(2):131-5. PubMed ID: 3100034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Pratt CB; Douglass EC; Etcubanas E; Goren MP; Green AA; Hayes FA; Horowitz ME; Meyer WH; Thompson EI; Wilimas JA
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):51-5. PubMed ID: 2495567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of ifosfamide in paediatric solid tumours.
    Pinkerton CR; Pritchard J
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S13-5. PubMed ID: 2758566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
    Schwartzman E; Scopinaro M; Angueyra N
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S11-2. PubMed ID: 2503255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide in pediatric solid tumors.
    Carli M; Passone E; Perilongo G; Bisogno G
    Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
    Tournade MF
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S31-3. PubMed ID: 2547529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of high-dose ifosfamide in children.
    Davies SM; Pearson AD; Craft AW
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S8-10. PubMed ID: 2503259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
    J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
    Magrath I; Sandlund J; Raynor A; Rosenberg S; Arasi V; Miser J
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S25-8. PubMed ID: 3815717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
    Antman KH; Montella D; Rosenbaum C; Schwen M
    Cancer Treat Rep; 1985 May; 69(5):499-504. PubMed ID: 3924401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide in pediatric malignancies.
    Jürgens H; Treuner J; Winkler K; Göbel U
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):46-50. PubMed ID: 2649985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of ifosfamide in children with recurrent solid tumours.
    Pinkerton CR; Rogers H; James C; Bowman A; Barbor PR; Eden OB; Pritchard J
    Cancer Chemother Pharmacol; 1985; 15(3):258-62. PubMed ID: 4053269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
    Ninane J; Baurain R; de Kraker J; Ferster A; Trouet A; Cornu G
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S2-6; discussion S7. PubMed ID: 2503256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of ifosfamide in paediatric cancer.
    Advani SH
    Aust N Z J Med; 1998 Jun; 28(3):410-3. PubMed ID: 9673760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
    Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Hematol Oncol; 1991; 9(4-5):189-96. PubMed ID: 1743622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
    Pratt CB; Green AA; Horowitz ME; Meyer WH; Etcubanas E; Douglass E; Hayes FA; Thompson E; Wilimas J; Igarashi M
    J Clin Oncol; 1986 Aug; 4(8):1253-61. PubMed ID: 3090210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
    Pratt CB; Meyer WH; Douglass EC; Bowman L; Wilimas J; Ochs J; Marina N; Avery L; Thompson EI
    Cancer; 1993 Jun; 71(11):3661-5. PubMed ID: 8490914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.